ClinicalTrials.gov
ClinicalTrials.gov Menu

IP3R Modulation by Cancer Genes in Mesothelioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03558932
Recruitment Status : Not yet recruiting
First Posted : June 15, 2018
Last Update Posted : June 15, 2018
Sponsor:
Information provided by (Responsible Party):
Yserbyt Jonas, KU Leuven

Brief Summary:
Obtaining pleural biopsies in cases of malignant mesothelioma to detect molecular mechnisms and signal transduction

Condition or disease Intervention/treatment
Malignant Mesothelioma Diagnostic Test: pleural biopsy

Study Type : Observational
Estimated Enrollment : 20 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: IP3R Modulation by Cancer Genes Bcl-2 & PKM2 in Mesothelioma
Estimated Study Start Date : January 2019
Estimated Primary Completion Date : December 2023
Estimated Study Completion Date : June 2024

Resource links provided by the National Library of Medicine



Intervention Details:
  • Diagnostic Test: pleural biopsy
    diagnostic sampling


Primary Outcome Measures :
  1. Pleural biopsy [ Time Frame: 5 years ]
    Biopsy


Other Outcome Measures:
  1. Immunoblotting [ Time Frame: 5 years ]
    biopsy

  2. Cytometric analysis (FACS-based approaches) [ Time Frame: 5 years ]
    biopsy

  3. Live cell imaging for Ca2+-signaling [ Time Frame: 5 years ]
    biopsy


Biospecimen Retention:   Samples Without DNA
pleural biopsies


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
mesothelioma
Criteria

Inclusion Criteria:

  • suspicion of mesothelioma
  • referral for diagnostic thoracoscopy

Exclusion Criteria:

  • contra-indication for thoracoscopy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03558932


Contacts
Contact: Jonas Yserbyt +32 16 34 68 01 jonas.yserbyt@uzleuven.be

Sponsors and Collaborators
KU Leuven
Investigators
Principal Investigator: Jonas Yserbyt Catholic university Leuven

Responsible Party: Yserbyt Jonas, Principal Investigator, KU Leuven
ClinicalTrials.gov Identifier: NCT03558932     History of Changes
Other Study ID Numbers: IP3mesov1
First Posted: June 15, 2018    Key Record Dates
Last Update Posted: June 15, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Mesothelioma
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Mesothelial